<b>Gapping down</b><br/><br/><b>In reaction to disappointing earnings/guidance: </b>CONN -40.2%, UTIW -6.6%, PLAB -6.3%, AEY -5.9%, HRB -5.6%, PBY -5.1%, GTIM -3.1%, MTL -3%, HDS -2.6%, VZ -1.8% (co expects that Q4 impacts of its promotional offers, together with the strong customer volumes this quarter, will put short-term pressure on its wireless segment EBITDA and EBITDA service margin), ABM -0.9%<br/><br/><b>M&A news:</b> MRK -2.5% (issues statement regarding CUBICIN patent litigation; reaffirms Cubist (CBST) transaction to proceed as planned - expected to close in first quarter of 2015), CBST -0.8%.<br/><br/><b>Select financial related names showing weakness:</b> BCS -2.3%, IRE -1.7%, DB -1.5%, HSBC -1.4%, BAC -1.1%, C -1.1%.<br/><br/><b>Select metals stocks trading lower:</b> AA -2.7%, BHP -2.2%, X -2.0%, RIO -1.9%<br/><br/><b>Select Chinese names showing early weakness</b>: JRJC -3.8%, LFC -3.4%, BABA -2.4%, JD -1.7%<br/><br/><b>Other news:</b> ANV -12.9% (announced public offering of common stock and warrants, size not disclosed), NBG -11.2% (Greece mkts down 11% today), GREK -10.5% (Greece ETF, gov called for snap elections), TASR -5.9% (unfavorable commentary on Monday's Mad Money), MANU -5.8% (announced the offering of 3 mln shares of its Class A Ordinary Shares by a selling shareholder), SAVE -5.3% (provided Q4 and 2015 guidance - co noticed some 'dilutive pricing arising from the change in capacity related to the expiration of the Wright Amendment'), TMUS -4.3% (announced proposed public offering of 17,391,305 shares of mandatory convertible preferred stock, with a liquidation preference of $50 per share), PBR -3.5% (still checking), PES -3.5% (expects CapEx to be reduced to $195-215 mln), SHPG -2.8% (still checking), INSY -2.8% (granted orphan drug designation to its Liposome Entrapped Paclitaxel Easy to Use candidate for the treatment of gastric cancer), TSLA -2.5% (most likely down with market weakness, however co officially launches in Australia), SD -2.4% (declared semi-annual preferred stock dividend fo $4.25 per share), BTE -2.3% (announces 2015 budget and change to dividends), TWTR -1.8% (likely down in tandem with market weakness), LHO -1.8% (announced sale of 7.6 mln common shares), ABGB -1.7% (still checking), YHOO -1.7% (likely in sympathy with BABA), AAPL -1.4% (likely down in tandem with market weakness), VALE -1.1% (announced that it entered into an investment agreement with Mitsui & Co), AMZN -1.1% (ChannelAdvisor reported Amazon's (AMZN) November SSS +35.7%)<br/><br/><b>Analyst comments: </b>SAVE -5.3% (downgraded to Mkt Perform from Outperform at Raymond James), SHPG -2.7% (downgraded to Neutral from Buy at BofA/Merrill), SEIC -2% (downgraded to Mkt Perform from Outperform at Keefe Bruyette), VZ -1.9% (downgraded to Neutral from Outperform at Robert W. Baird), M -1.7% (downgraded to Neutral from Overweight at Atlantic Equities), LPX -1.2% (downgraded to Neutral from Buy at Longbow), GSK -1% (downgraded to Underperform from Neutral at BofA/Merrill).<br/><br/><b>Gapping up</b><br/><br/><b>In reaction to strong earnings/guidance:</b> AZO +3.3%, BURL +3.2%<br/><br/><b>M&A news:</b> TLM +4.8% (confirms it has been approached by a number of parties, including Repsol (REPYY), with regards to various transactions)<br/><br/><b>Select mining stocks trading higher</b>: ABX +2.5%, AUY +2.5%, GG +2.4%, PAAS +2%, NEM +1.9%, SLV +1.9%, HMY +1.7%<br/><b><br/>Select oil/gas related names showing strength: </b>HK +3.2%, SDRL +2.9%, DO +1.1%, GDP +1%, RIG +0.8%<br/><br/><b>Other news</b>: BLUE +51.2% (announced data demonstrating first four patients with beta-thalassemia major treated with LentiGlobin are transfusion-free), CANF +12% (will initiate a pre-clinical development program of its next generation drug CF602 for the indication of sexual dysfunction), MZOR +9.2% (receives purchase orders for three Renaissance systems in Asia), CTP +8.6% (announces withdrawal of public offering), PDCE +5.8% (announced 2015 capital budget of $557 mln and production guidance of 13.8-14.5 mln Boe or ~50% yoy growth), PQ +4.6% (announces significant discovery at its Thunder Bayou Prospect), LLY +3% (Eli Lilly and Incyte (INCY) announced positive top-line results from Phase 3 Trial of Baricitinib in moderate to severe rheumatoid arthritis; met its primary endpoint ), HSP +2.3% (received a favorable ruling in patent case against Cubist/Merck (CBST, MRK)) CTIC +1.3% (presented at ASH)<br/><br/><b>Analyst comments: </b>LULU +1.9% (upgraded to Outperform from Market Perform at Wells Fargo), FGEN +1.6% (initiated with a Buy at Goldman and initiated with a Outperform at RBC Capital Mkts), AEO +1.3% (upgraded to Outperform at Oppenheimer), LECO +0.7% (upgraded to Buy from Neutral at Longbow)<br/><br/>Allikas: <i>Briefing.com</i>